Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Fate Therapeutics launched through $14.6mm Series A
20 Apr 2009
Fate Therapeutics (adult stem cell biology) was recently launched through a two-tranche $14.6mm Series A round backed by Arch Venture Partners, Polaris Venture Partners, OVP Venture Partners, and Venrock. The start-up has a small-molecule platform that modulates adult stem cells to mimic the beneficial characteristics of embryonic stem cells.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?